Planning for the Future: A Review of Cancer in Pregnancy and Fertility





Authors: Allison Reed, PharmD, BCPS, BCOP Institution: The Ohio State University James Cancer Center

Cancer and Fertility in Adults¹⁻⁴

- Surgery
- Surgery to reproductive organs, endocrine glands, abdomen, or pelvis may affect a patient's ability to have children
- Men: surgery may injure nerves in prostate or testicles
- Women: depending on stage and location of cancer, extensive surgery may be required, resulting in loss of reproductive organs
- Radiation
- Radiation to the brain may affect pituitary gland, due to proximity, which can affect testosterone, follicle-stimulating hormone, luteinizing hormone, and gonadotropin-releasing hormone
- Radiation to pelvis or reproductive organs may affect sperm or ovaries
- Mechanisms exist to protect reproductive organs during radiation treatment
- Antineoplastic agents
- Alkylating agents and anthracyclines, which are the backbone for many regimens, pose the biggest risk to reproductive organs
- These agents are especially worrisome as they are utilized frequently in many pediatric regimens as well

Antineoplastic and the Effects on Fetuses⁵⁻⁸

- Administration during pregnancy
- Administration of chemotherapy during the first trimester increases the risk of congenital abnormalities
- If chemotherapy needs to be administered during the first trimester, monotherapy is associated with a lower risk of abnormalities
- The risk of abnormalities when chemotherapy is administered during the second and third trimesters is comparable to women who do not received chemotherapy during pregnancy.
- Treatment should be stopped when the mother is 33 weeks along to avoid the mother delivering during nadir
- Anti-metabolites: teratogenic; can cause significant abnormalities, miscarriage, or stillbirth
- Rituximab: B-cells may be decreased in child
- Tamoxifen: increases risk of fetal abnormalities
- However, later stages of pregnancy has higher levels of estrogen, which can worsen hormone related cancers

Safe Antineoplastic Agents During Pregnancy⁵-6,8-9

- Frequency
- Administering treatment weekly is more favorable compared to less frequent administration due to the smaller chance of myelosuppression and shorter nadirs
- Chemotherapy
 - Generally, lower rates of placental transfer during second and third trimesters are considered safer
 - Some preferred agents: doxorubicin, cyclophosphamide, vincristine
- Tyrosine kinase inhibitors
- Safe to give in the second and third trimesters
- Can cross into the placenta during the first trimester
- Example: imatinib administered during the first trimester places the fetus at greater risk of anomalies or miscarriage
- Monoclonal antibodies
- Do not cross into the placenta until after week 15 because they are large and hydrophilic molecules
- Example: 75% of women who received trastuzumab in the first trimester only gave birth to healthy babies compared to 41.7% of women who received trastuzumab in the second or third trimester
- Most common side effect: anhydramnios or oligohyramnios

opment period	Fetal develop			od	nesis perio	Organoge			Implantation period		
3 rd trimester	2 nd trimester				ter	1 st trimest					
32 38	16	9	8	7	6	5	4	3	2	1	
a 6											
STE ST	30	()	alle)	1	£)	(3)	The same	3	9	①	
)		SAN	and the	Se Jan		5	()	S. S.		•	

Cytotoxic agents	Extremely high risk	Observed in 20%	Relatively high rate of complications in the mother and fetus (e.g., IUGR)
Monoclonal antibodies	Moderately high risk	Relatively low	High rate of drug-specific complications (e.g., oligohydramnios and lymphopenia)
Tyrosine kinase inhibitors	Moderately high risk	Potential	Complications may occur in the mother and fetus (insufficient data)
	Death of embryo and spontaneous abortion common	Major malformation	Functional defects Minor malformation

Methods of Fertility Preservation¹⁰

Women	Men
Oocyte cryopreservation	Semen cryopreservation
Ovarian shielding	Testicular shielding
Embryo cryopreservation	Testicular sperm extraction
Ovarian tissue cryopreservation (experimental)	Testicular tissue freezing (experimental)
Oophoropexy	
Radical trachelectomy	
Gonadotropin-releasing hormone agonist	

- Oophoropexy: a procedure to move the ovaries away from the field of radiation temporarily
- Radical trachelectomy: extraction of the cervix, lymph nodes, and the upper vagina
- The remaining vaginal area and the uterus are then connected via a band that acts the cervix
- Used for patients with cervical cancer
- Ovarian tissue cryopreservation: surgery that involves the removal of ovarian tissue, freezing the tissue, thawing at a later date, and surgically reattachment
 - Only an option for people who have not gone through puberty
 - Few pregnancies have been reported via this method and more research is needed
- Testicular tissue cryopreservation: surgery that involves the removal of testicular tissue, freezing the tissue, thawing at a later date, and surgically reattachment
- Only considered an option for people who have not gone through puberty
- Currently only recommended as part of a clinical trial

References

- 1. Fertility Issues in Girls and Women with Cancer. Reviewed February 24, 2020. Accessed February 1, 2023. https://www.cancer.gov/about-cancer/treatment/side-effects/fertility-women.
- Fertility Issues in Boys and Men with Cancer. Reviewed February 24, 2020. Accessed February 1, 2023. https://www.cancer.gov/about-cancer/treatment/side-effects/fertility-men.
- 3. Fertility Concerns and Preservation for Men. ASCO. Published September 2019. Accessed February 1, 2023.
- https://www.cancer.net/navigating-cancer-care/dating-sex-and-reproduction/fertility-concerns-and-preservation-men.
- 4. Fertility Concerns and Preservation for Women. ASCO. Published September 2019. Accessed February 1, 2023.
- https://www.cancer.net/navigating-cancer-care/dating-sex-and-reproduction/fertility-concerns-and-preservation-women.
 5. Peccartori FA, Azim Jr HA, Orecchia R, et al. Cancer, pregnancy, and fertility: ESMO clinical practice guidelines for diagnosis, treatment, and
- follow up. *Ann Oncol*. 2013; 24 Suppl 6: vi160-170. DOI: 10.1093/annonc/mdt199.

 6. Esposito S, Tenconi R, Preti V, Groppali E, Principi N. Chemotherapy against cancer during pregnancy: A systematic review on neonatal
- outcomes. *Medicine* 2015; 95(38): e4899. DOI: 10.1097/MD.0000000000004899.

 7. Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. *Semin Oncol*. 1989;16(5):337–46.
- 8. Miyamoto S, Yamada M, Kasai Y, Miyauchi A, Andoh K. Anticancer drugs during pregnancy. *Jpn J Clin Oncol*. 2016;46(9):795-804. DOI: 10.1093/jjco/hyw073.
- 9. Bader AA, Schlembach D, Tamussino KF, Pristauz G, Petru E. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. *Lancet Oncol*. 2007;8(1):79-81. DOI: 10.1016/S1470-2045(06)71014-2.
- 10. Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. *J Clin Oncol*. 2018;36(19):1994-2001. DOI: 10.1200/JCO.2018.78.1914.